Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Denifanstat in Hepatic Impairment
NCT05835180Phase 1Completed
- Sponsor
- Sagimet Biosciences
- Start
- May 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of denifanstat in Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by Sagimet Biosciences. Primary endpoints: Total TVB-2640 plasma concentration-time (AUC) at steady state at Day 4, Unbound TVB-2640 plasma concentration-time (AUC) at steady state at Day 4 and 3 more. Started May 2023; status: completed.
02
Drugs
denifanstat
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05835180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05835180.